Want to see GB:PXS full AI Analyst Report?
Provexis (PXS) AI Stock Analysis
Provexis
(LSE:PXS)
The score is primarily constrained by continued losses, negative returns, and weak valuation despite debt-free finances, improving revenue, and a recent improvement in cash flow. Technical conditions are mixed, with the price above shorter-term averages but below longer-term averages and momentum indicators lacking confirmation.
Provexis (PXS) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 18.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 607.83K
- Price to Earnings (P/E)
- -80.0
- Beta (1Y)
- -0.06
- Revenue Growth
- -2.14%
- EPS Growth
- 0.00%
- Country
- UK
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Provexis Business Overview & Revenue Model
Company Description
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tom...
Provexis Financial Statement Overview
Summary
Revenue and operating cash flow improved, and the company has no reported debt. However, persistent net and operating losses, negative return on equity, declining equity, and inconsistent cash generation indicate weak overall financial performance.
Income Statement
20Very NegativeBalance Sheet
65PositiveCash Flow
45Neutral| Breakdown | TTM | Sep 2025 | Sep 2024 | Mar 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 871.26K | 1.26M | 1.29M | 801.96K | 389.92K | 426.17K |
| Gross Profit | 428.97K | 510.89K | 532.94K | 283.80K | 294.42K | 380.05K |
| EBITDA | -610.13K | -491.94K | -449.63K | 0 | 0 | 0 |
| Net Income | -603.80K | -502.76K | -452.72K | -586.24K | -385.24K | -224.25K |
Balance Sheet | ||||||
| Total Assets | 841.84K | 1.30M | 1.01M | 498.04K | 845.99K | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 523.35K | 893.14K | 708.09K | 189.36K | 379.12K | 863.87K |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 230.95K | 722.92K | 248.21K | 307.45K | 188.34K | 157.91K |
| Stockholders Equity | 1.14M | 1.11M | 1.30M | 724.34K | 1.19M | 1.50M |
Cash Flow | ||||||
| Free Cash Flow | -544.53K | 179.84K | -338.90K | -191.50K | -519.85K | -213.79K |
| Operating Cash Flow | -544.53K | 179.84K | -338.90K | -191.50K | -519.85K | -213.54K |
| Investing Cash Flow | 2,789 | 5,210 | 1,929 | 1,734 | 887 | 78 |
| Financing Cash Flow | 586.89K | 0 | 857.63K | 0 | 35.10K | 1.05M |
Provexis Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Negative. The current price of 0.80 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 0.99, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.30 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PXS.
Provexis Peers Comparison
Overall Rating
GB:EAH59Neutral- GB:PXS44Neutral
GB:STX42Neutral
GB:CHLL38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:EAH | 59Neutral | GBP 64.71M | 29.57 | 2.55% | ― | 9.96% | 29.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:PXS | 44Neutral | GBP 18.77M | -80.00 | -44.68% | ― | -2.14% | 0.00% |
| GB:STX | 42Neutral | GBP 60.69M | -7.72 | 64.57% | ― | 36.19% | 60.75% |
| GB:CHLL | 38Underperform | GBP 888.98K | -0.00 | 233.76% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:PXS | Provexis plc | 0.80 | 0.22 | 37.93% | |
| GB:EAH | Eco Animal Health | 95.50 | 12.50 | 15.06% | |
| GB:CHLL | Chill Brands Group PLC | 1.70 | -8.80 | -83.81% | |
| GB:HELD | Mountfield Group plc | 0.90 | -0.05 | -5.26% | |
| GB:STX | Shield Therapeutics | 5.65 | -1.40 | -19.86% |
Provexis Corporate Events
Provexis rides surging Fruitflow demand as margins set to improve
PositiveProvexis reported annual revenue of £1.26m for the year to 31 March 2026, broadly flat year on year, but delivered a record £900k in second-half sales as demand for its Fruitflow heart-health ingredient accelerated among existing and new cu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026